Viking Global Investors’s Day One Biopharmaceuticals DAWN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,558,563
Closed -$35.6M 92
2024
Q3
$35.6M Hold
2,558,563
0.13% 77
2024
Q2
$35.3M Hold
2,558,563
0.14% 74
2024
Q1
$42.3M Hold
2,558,563
0.16% 73
2023
Q4
$37.4M Hold
2,558,563
0.14% 70
2023
Q3
$31.4M Hold
2,558,563
0.13% 72
2023
Q2
$30.5M Buy
2,558,563
+1,000,000
+64% +$13.1M 0.13% 77
2023
Q1
$20.8M Hold
1,558,563
0.1% 74
2022
Q4
$33.5M Hold
1,558,563
0.17% 68
2022
Q3
$31.2M Sell
1,558,563
-298,861
-16% -$6.36M 0.14% 75
2022
Q2
$33.2M Buy
1,857,424
+700,000
+60% +$7.23M 0.15% 72
2022
Q1
$11.5M Hold
1,157,424
0.05% 88
2021
Q4
$19.5M Sell
1,157,424
-53,972
-4% -$1.11M 0.06% 101
2021
Q3
$28.7M Sell
1,211,396
-130,000
-10% -$3.12M 0.08% 91
2021
Q2
$30.5M Buy
+1,341,396
New +$28M 0.09% 83

Other funds holding DAWN

Viking Global Investors's DAWN Position: Q4 2024 in Review

Viking Global Investors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 2,558,563 shares — an estimated $35.6M sold.

Viking Global Investors first reported a position in DAWN in Q2 2021 and held it in 14 quarters. The position peaked at $42.3M in Q1 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Viking Global Investors reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Viking Global Investors sold 2,558,563 Day One Biopharmaceuticals shares in Q4 2024, an estimated $35.6M.
  • Viking Global Investors first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 14 quarters.
  • Viking Global Investors's Day One Biopharmaceuticals position peaked at $42.3M in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Viking Global Investors's 13F filing for Q4 2024, filed 14 Feb 2025.